<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04034459</url>
  </required_header>
  <id_info>
    <org_study_id>FIRE-4.5</org_study_id>
    <nct_id>NCT04034459</nct_id>
  </id_info>
  <brief_title>FOLFOXIRI Plus Cetuximab vs. FOLFOXIRI Plus Bevacizumab 1st-line in BRAF-mutated mCRC</brief_title>
  <acronym>AIO-KRK-0116</acronym>
  <official_title>Randomised Study to Investigate FOLFOXIRI Plus Cetuximab vs. FOLFOXIRI Plus Bevacizumab as First-line Treatment of BRAF-mutated Metastatic Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ludwig-Maximilians - University of Munich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ludwig-Maximilians - University of Munich</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Once randomisation has been completed, the study treatment should be started preferably&#xD;
      immediately; at the latest within one week following randomisation.&#xD;
&#xD;
      The patients will be randomised in a ratio of 1:2 to the following two treatment arms.&#xD;
&#xD;
      Patients in both treatment arms will receive standard chemotherapy with FOLFOXIRI as&#xD;
      background treatment, which can be de-escalated to FOLFIRI in case of toxicity.&#xD;
&#xD;
      Standard arm A:&#xD;
&#xD;
      The patient will be treated with FOLFOXIRI plus bevacizumab for up to 12 cycles (24 weeks) or&#xD;
      until progression (if the latter occurs before completing the 12 cycles). Within the 12&#xD;
      cycles, the FOLFOXIRI plus bevacizumab regimen may be de-escalated, owing to toxicity, to&#xD;
      FOLFIRI and bevacizumab at the treating physician's discretion.&#xD;
&#xD;
      After 12 cycles of the study treatment, a switch to a maintenance regimen with a&#xD;
      fluoropyrimidine (5-FU infusion or capecitabine) plus bevacizumab, administered until&#xD;
      progression occurs, is recommended. The recommended maintenance phase of the study is not&#xD;
      part of the study treatment. However, maintenance therapy will be counted as first-line&#xD;
      therapy.&#xD;
&#xD;
      Experimental arm B:&#xD;
&#xD;
      The patient will be treated with FOLFOXIRI plus weekly administration of cetuximab for up to&#xD;
      12 cycles (24 weeks) or until progression (if the latter occurs before completing the 12&#xD;
      cycles). Within the 12 cycles, the FOLFOXIRI plus cetuximab regimen may be de-escalated owing&#xD;
      to toxicity, to FOLFIRI and cetuximab at the treating physician's discretion.&#xD;
&#xD;
      After 12 cycles, a switch to a maintenance regimen with 5-FU and cetuximab or with irinotecan&#xD;
      and cetuximab, administered until progression occurs, is recommended. The recommended&#xD;
      maintenance phase of the study is not part of the study treatment. However, maintenance&#xD;
      therapy will be counted as first-line therapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 25, 2016</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">November 1, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Response Rate (ORR)</measure>
    <time_frame>up to 48 months</time_frame>
    <description>(overall response rate) measured in percentage of all treated patients according to RECIST 1.1 criteria</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>up to 60 months</time_frame>
    <description>Investigation of progression-free survival (PFS) from randomisation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>up to 60 months</time_frame>
    <description>Investigation of overall survival (OS) from randomisation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigation of Early Tumour Shrinkage (ETS) as early-on-Treatment predictor for treatment</measure>
    <time_frame>up to 48 months</time_frame>
    <description>Investigation of early tumour shrinkage (ETS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigation of Depth of Response (DpR) to define nadir for tumour response.</measure>
    <time_frame>up to 48 months</time_frame>
    <description>Investigation of depth of response (DpR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigation of Molecular Biomarkers for Prediction of an Anti-EGFR Treatment</measure>
    <time_frame>up to 48 months</time_frame>
    <description>Investigation of molecular biomarkers for prediction of sensitivity and secondary resistance of an anti-EGFR treatment with cetuximab (including tumour biopsies and liquid biopsies from blood samples)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prospective Analysis of Tumour Marker Level Evolution (CEA and CA 19-9)</measure>
    <time_frame>up to 48 months</time_frame>
    <description>Investigation of prospective analysis of tumour marker level evolution (CEA and CA 19-9)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]</measure>
    <time_frame>up to 48 months</time_frame>
    <description>Recording of the safety and tolerability (NCI-CTCAE version 4.03 criteria) of the treatment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">99</enrollment>
  <condition>Metastatic Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>FOLFOXIRI plus bevacizumab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>One cycle (cycle duration 14 days) consists of:&#xD;
Irinotecan 150 mg/m² iv, 30 - 90 min. day 1&#xD;
Folinic acid (racemic) 400 mg/m² iv, 120 min. day 1&#xD;
Oxaliplatin 85mg/m² day 1&#xD;
5-FU 3000 mg/m² iv over 48 h days 1-2&#xD;
Bevacizumab 5 mg/kg BW iv over 30 to 90* min day 1 *1st administration 90 min.; in case of good tolerability, second administration 60 min.; further administrations 30 min.&#xD;
Repeat administration every 2 weeks for a maximum of 12 cycles&#xD;
Dose adaptation at the treating physician's discretion.&#xD;
Switch to the recommended maintenance treatment with fluoropyrimidine and bevacizumab after the 8th cycle (following 2nd staging after baseline) is possible at the treating physician's discretion if response according to RECIST 1.1 (CR or PR) has been achieved.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FOLFOXIRI plus cetuximab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One cycle (cycle duration 14 days) consists of:&#xD;
Irinotecan 150 mg/m² iv, 30 - 90 min. day 1&#xD;
Folinic acid (racemic) 400 mg/m² iv, 120 min. day 1&#xD;
Oxaliplatin 85mg/m² day 1&#xD;
5-FU 3000 mg/m² iv over 48 h days 1-2&#xD;
Cetuximab initially 400 mg/m² with infusion rate of ≤5 mg/min., subsequently 250 mg/m² iv with infusion rate of ≤10 mg/min. days 1+8&#xD;
Repeat administration every two weeks up to a maximum of 12 cycles.&#xD;
Dose adaptation at the treating physician's discretion.&#xD;
Switch to the recommended maintenance treatment with 5-FU and cetuximab or irinotecan and cetuximab after the 8th cycle (following 2nd staging after baseline) is possible at the treating physician's discretion if response according to RECIST 1.1 (CR or PR) has been achieved.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>Bevacizumab 5 mg/kg BW iv over 30 to 90* min day 1</description>
    <arm_group_label>FOLFOXIRI plus bevacizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irinotecan</intervention_name>
    <description>Irinotecan 150 mg/m² iv, 30 - 90 min. day 1</description>
    <arm_group_label>FOLFOXIRI plus bevacizumab</arm_group_label>
    <arm_group_label>FOLFOXIRI plus cetuximab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Folinic acid</intervention_name>
    <description>Folinic acid (racemic) 400 mg/m² iv, 120 min. day 1</description>
    <arm_group_label>FOLFOXIRI plus bevacizumab</arm_group_label>
    <arm_group_label>FOLFOXIRI plus cetuximab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <description>Oxaliplatin 85mg/m² day 1</description>
    <arm_group_label>FOLFOXIRI plus bevacizumab</arm_group_label>
    <arm_group_label>FOLFOXIRI plus cetuximab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-FU</intervention_name>
    <description>5-FU 3000 mg/m² iv over 48 h days 1-2</description>
    <arm_group_label>FOLFOXIRI plus bevacizumab</arm_group_label>
    <arm_group_label>FOLFOXIRI plus cetuximab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cetuximab</intervention_name>
    <description>Cetuximab initially 400 mg/m² with infusion rate of ≤5 mg/min., subsequently 250 mg/m² iv with infusion rate of ≤10 mg/min. days 1+8</description>
    <arm_group_label>FOLFOXIRI plus cetuximab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed UICC stage IV adenocarcinoma of the colon or rectum with&#xD;
             metastases (metastatic colorectal cancer [mCRC]); metastases primarily non-resectable&#xD;
             or surgery refused by the patient&#xD;
&#xD;
          -  RAS wild-type tumour status (KRAS and NRAS exons 2, 3, 4) (proven in the primary&#xD;
             tumour or metastasis)&#xD;
&#xD;
          -  BRAF-mutant (V600E) tumour (proven in the primary tumour or metastasis)&#xD;
&#xD;
          -  Age ≥18 years&#xD;
&#xD;
          -  ECOG performance status 0-1&#xD;
&#xD;
          -  Patients suitable for chemotherapy administration&#xD;
&#xD;
          -  Patient's written declaration of consent obtained&#xD;
&#xD;
          -  Estimated life expectancy &gt; 3 months&#xD;
&#xD;
          -  Presence of at least one measurable lesion according to the RECIST 1.1 - criteria&#xD;
             (chest X-ray in two planes or chest CT and abdominal CT 4 weeks or less before&#xD;
             randomisation)&#xD;
&#xD;
          -  Primary tumour tissue available and patient consents to storage and molecular and&#xD;
             genetic profiling of the tumour material. Molecular profiling of blood samples is&#xD;
             optionally performed.&#xD;
&#xD;
          -  Females of childbearing potential (FCBP) and men must agree to use effective&#xD;
             contraceptive measures (Pearl index &lt;1) for the duration of the study treatment and&#xD;
             for at least 6 months after last administration of the study medication. A female&#xD;
             subject will be considered to be of child-bearing potential unless she is ≥ 50 years&#xD;
             of age as well as has had a natural menopause for at least 2 years or has been&#xD;
             surgically sterilised.&#xD;
&#xD;
          -  Adequate bone marrow function:&#xD;
&#xD;
          -  Leukocytes ≥ 3.0 x 109/L with neutrophils ≥ 1.5 x 109/L&#xD;
&#xD;
          -  Thrombocytes ≥ 100 x 109/L,&#xD;
&#xD;
          -  Haemoglobin ≥ 5.6 mmol/L (equivalent to 9 g/dL)&#xD;
&#xD;
          -  Adequate hepatic function:&#xD;
&#xD;
          -  Serum bilirubin ≤ 1.5 x upper limit of normal (ULN),&#xD;
&#xD;
          -  ALAT and ASAT ≤ 2.5 x ULN (in case of hepatic metastasis, ALAT and ASAT ≤ 5 x ULN)&#xD;
&#xD;
          -  INR &lt; 1.5 and aPTT &lt; 1.5 x ULN (patients without anticoagulation). Therapeutic&#xD;
             anticoagulation is allowed if INR and aPTT have remained stable within the therapeutic&#xD;
             range for at least 2 weeks.&#xD;
&#xD;
          -  Adequate renal function:&#xD;
&#xD;
          -  Serum creatinine ≤ 1.5 x ULN or creatinine clearance (calculated according to&#xD;
             Cockcroft and Gault) ≥ 50mL/min.&#xD;
&#xD;
          -  Adequate cardiac function: ECG and echocardiogram with a LVEF of ≥ 55%&#xD;
&#xD;
          -  No previous chemotherapy for metastatic disease (prior radiotherapy of&#xD;
             metastasis/metastases without application of chemotherapy permitted provided that no&#xD;
             irradiated metastasis is selected as target lesion)&#xD;
&#xD;
          -  Time interval since last administration of any previous neoadjuvant/adjuvant&#xD;
             chemotherapy or radiochemotherapy ≥6 months&#xD;
&#xD;
          -  Any relevant toxicities of previous treatments must have subsided to grade 0&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Grade III or IV heart failure (NYHA classification)&#xD;
&#xD;
          -  Myocardial infarction, unstable angina pectoris, balloon angioplasty (PTCA) with or&#xD;
             without stenting within the past 12 months before randomisation&#xD;
&#xD;
          -  Pregnancy (absence of pregnancy has to be ascertained by a beta hCG test) or breast&#xD;
             feeding&#xD;
&#xD;
          -  Medical or psychological impairments associated with restricted ability to give&#xD;
             consent or not allowing conduct of the study&#xD;
&#xD;
          -  Additional cancer treatment (chemotherapy, radiation, immune therapy or hormone&#xD;
             treatment) during the study treatment. Treatments that are conducted as part of an&#xD;
             anthroposophical or homeopathic treatment approach, e.g. mistletoe therapy, do not&#xD;
             represent an exclusion criterion.&#xD;
&#xD;
          -  Previous chemotherapy for the colorectal cancer with exception of chemotherapy or&#xD;
             radiochemotherapy given as neoadjuvant or adjuvant treatment with curative intent,&#xD;
             completed ≥6 months before entering the study.&#xD;
&#xD;
          -  Participation in a clinical study or experimental drug treatment within 30 days prior&#xD;
             to study inclusion or within a period of 5 half-lives of the substances administered&#xD;
             in a clinical study or during an experimental drug treatment prior to inclusion in the&#xD;
             study, depending on which period is longest, or simultaneous participation in another&#xD;
             clinical study while taking part in the study&#xD;
&#xD;
          -  Known hypersensitivity or allergic reaction to any of the following substances:&#xD;
             5-fluorouracil, folinic acid, cetuximab, irinotecan, bevacizumab, oxaliplatin and&#xD;
             chemically related substances and/or hypersensitivity to any of the excipients of any&#xD;
             of the aforementioned substances&#xD;
&#xD;
          -  Known hypersensitivity to CHO (Chinese hamster ovary cells) - cell products or other&#xD;
             recombinant human or humanised antibodies&#xD;
&#xD;
          -  Patients with confirmed cerebral metastases. In case of clinical suspicion of brain&#xD;
             metastases, a cranial CT or MRI must be performed to rule out brain metastases before&#xD;
             study inclusion.&#xD;
&#xD;
          -  History of acute or subacute intestinal occlusion or chronic inflammatory bowel&#xD;
             disease or chronic diarrhoea.&#xD;
&#xD;
          -  Symptomatic peritoneal carcinosis&#xD;
&#xD;
          -  Severe, non-healing wounds, ulcers or bone fractures&#xD;
&#xD;
          -  Patients with active infection (including confirmed HIV and/or HBV/HCV infection). In&#xD;
             case of clinical suspicion of the presence of HIV or HBV/HCV infection, the latter&#xD;
             should be ruled out before study inclusion.&#xD;
&#xD;
          -  Requirement for immunisation with live vaccine during the study treatment.&#xD;
&#xD;
          -  Uncontrolled hypertension&#xD;
&#xD;
          -  Marked proteinuria (nephrotic syndrome)&#xD;
&#xD;
          -  Arterial thromboembolism or severe haemorrhage within 6 months prior to randomisation&#xD;
             (with the exception of tumour bleeding before tumour resection surgery)&#xD;
&#xD;
          -  Haemorrhagic diathesis or tendency towards thrombosis&#xD;
&#xD;
          -  Known DPD deficiency (specific screening not required)&#xD;
&#xD;
          -  Known glucuronidation deficiency (Gilbert's syndrome) (specific screening not&#xD;
             required)&#xD;
&#xD;
          -  History of a second malignancy during the 5 years before inclusion in the study or&#xD;
             during participation in the study, with the exception of a basal cell or squamous cell&#xD;
             carcinoma of the skin or cervical carcinoma in situ, if these were treated curatively.&#xD;
&#xD;
          -  Known history of alcohol or drug abuse&#xD;
&#xD;
          -  A significant concomitant disease, in particular chronic hepatic or renal disease,&#xD;
             chronic inflammatory or autoimmune diseases, ruling out the patient's participation in&#xD;
             the study according to investigator's judgement.&#xD;
&#xD;
          -  Absent or restricted legal capacity&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Volker Heinemann, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medizinische Klinik III</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sebastian Stintzing, Prof. Dr.</last_name>
    <phone>+49 89 4400 0</phone>
    <email>sebastian.stintzing@med.uni-muenchen.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Volker Heinemann, Prof. Dr.</last_name>
    <phone>+49 89 4400 0</phone>
    <email>volker.heinemann@med.uni-muenchen.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Klinikum der Universitaet Muenchen</name>
      <address>
        <city>Munich</city>
        <zip>81377 München</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Volker Heinemann, PRof. Dr.</last_name>
      <phone>+49 89 4400 0</phone>
      <email>volker.heinemann@med.uni-muenchen.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>December 22, 2017</study_first_submitted>
  <study_first_submitted_qc>July 24, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 26, 2019</study_first_posted>
  <last_update_submitted>July 24, 2019</last_update_submitted>
  <last_update_submitted_qc>July 24, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ludwig-Maximilians - University of Munich</investigator_affiliation>
    <investigator_full_name>PD Dr. med. Volker Heinemann</investigator_full_name>
    <investigator_title>Director Comprehensive cancer center</investigator_title>
  </responsible_party>
  <keyword>FIRE</keyword>
  <keyword>mCRC</keyword>
  <keyword>AIO</keyword>
  <keyword>BRAF</keyword>
  <keyword>FOLFOXIRI</keyword>
  <keyword>Cetuximab</keyword>
  <keyword>Bevacizumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Folic Acid</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Cetuximab</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

